Indomethacin Tablets Market Size, Share, Growth, and Industry Analysis, By Type (Indomethacin Tablets, Indomethacin Enteric Coated Tablets), By Application (Hospital, Clinic, Other), Regional Insights and Forecast to 2035

Indomethacin Tablets Market Overview

Indomethacin Tablets Market size is anticipated to be worth USD 514.86 million in 2026 and is expected to reach USD 813.4 million by 2035 at a CAGR of 5.22%.

The Indomethacin Tablets Market is witnessing strong demand across hospital pharmacies, retail pharmacies, and clinical treatment centers due to the increasing prevalence of inflammatory disorders, arthritis, musculoskeletal conditions, and post-surgical pain management requirements. Indomethacin tablets are widely prescribed nonsteroidal anti-inflammatory drugs (NSAIDs) used in the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, gout, and bursitis. More than 350 million individuals globally suffer from arthritis-related disorders, while nearly 25% of adults above 60 years require anti-inflammatory medications regularly. The growing elderly population and rising orthopedic procedures are significantly contributing to the expansion of the Indomethacin Tablets Market. Generic pharmaceutical manufacturing accounts for over 72% of total tablet distribution volumes worldwide. Increasing penetration of enteric-coated formulations, improved pharmaceutical distribution networks, and higher prescription rates in chronic pain management continue to support the Indomethacin Tablets Market Analysis and Industry Report across developed and emerging healthcare economies.

The USA remains one of the most significant contributors to the Indomethacin Tablets Market due to increasing musculoskeletal disorders and chronic inflammatory disease prevalence. More than 58 million adults in the United States are diagnosed with arthritis-related conditions, while approximately 21% of orthopedic prescriptions include NSAID-based formulations for pain management. Around 68% of rheumatology clinics in the country regularly prescribe indomethacin formulations for moderate-to-severe inflammation management. Hospital pharmacy distribution contributes nearly 46% of prescription dispensing volumes. The growing elderly population, accounting for over 17% of the total population, continues to increase demand for anti-inflammatory oral medications. Generic drug penetration exceeds 89% in the U.S. pharmaceutical sector, encouraging higher accessibility of indomethacin tablets through retail pharmacies, healthcare chains, and outpatient treatment facilities.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: Over 64% of chronic arthritis patients require NSAID-based therapies, while 48% of orthopedic prescriptions include anti-inflammatory tablet formulations for long-term pain management.
• Major Market Restraint: Nearly 37% of patients report gastrointestinal side effects associated with NSAIDs, while 29% of elderly patients require monitored dosage adjustments.
• Emerging Trends: More than 44% of pharmaceutical manufacturers are focusing on enteric-coated tablets, while 33% of healthcare providers prefer low-irritation NSAID formulations.
• Regional Leadership: North America accounts for approximately 39% prescription consumption volumes, while Asia-Pacific contributes nearly 34% of generic tablet manufacturing output.
• Competitive Landscape: Around 61% of pharmaceutical companies are expanding generic NSAID portfolios, while 42% focus on improved oral dosage formulation technologies.
• Market Segmentation: Standard indomethacin tablets contribute nearly 57% of total prescription demand, while enteric-coated tablets account for approximately 43% of distribution volumes.
• Recent Development: Nearly 31% of manufacturers increased production capacities for anti-inflammatory drugs, while 27% introduced upgraded coated tablet technologies for improved tolerability.

Indomethacin Tablets Market Latest Trends

The Indomethacin Tablets Market Trends indicate growing adoption of advanced oral anti-inflammatory formulations across healthcare systems worldwide. Pharmaceutical manufacturers are increasingly focusing on enteric-coated tablets to minimize gastrointestinal complications associated with conventional NSAIDs. More than 43% of newly launched indomethacin products now feature modified-release or protective coating technologies. Increasing demand from orthopedic and rheumatology departments continues to strengthen market penetration in hospitals and specialty clinics. Approximately 52% of arthritis-related prescriptions globally involve oral NSAID medications due to ease of administration and rapid pain management outcomes. Generic drug manufacturing expansion in Asia-Pacific has improved global product availability by over 38%, supporting supply chain efficiency and affordability. Retail pharmacy chains account for nearly 49% of overall tablet distribution, while hospital pharmacies contribute close to 36%. Digital prescription systems and telemedicine adoption have increased online pharmaceutical dispensing by approximately 26%, improving accessibility of indomethacin tablets in remote regions. Pharmaceutical companies are also investing in pediatric-safe packaging, low-dose formulations, and enhanced dissolution technologies to improve patient compliance and therapeutic effectiveness across diverse treatment applications.

Indomethacin Tablets Market Dynamics

DRIVER

"Rising prevalence of arthritis and inflammatory disorders"

The increasing prevalence of arthritis, gout, and chronic inflammatory disorders is a major growth driver for the Indomethacin Tablets Market. More than 350 million people globally experience arthritis-related conditions, while nearly 70% of elderly patients report chronic joint pain requiring long-term anti-inflammatory therapy. Rheumatoid arthritis affects approximately 1% of the global population, while osteoarthritis prevalence continues rising due to sedentary lifestyles and obesity-related complications. Around 46% of orthopedic specialists prefer NSAID-based oral medications for rapid pain reduction and inflammation management. The growing number of sports injuries and post-operative rehabilitation cases is also increasing prescription volumes. More than 28% of pain management prescriptions in hospital settings involve oral anti-inflammatory drugs. Increasing healthcare awareness campaigns and improved access to pharmaceutical treatments across developing economies are supporting higher patient diagnosis rates. Generic indomethacin formulations now account for over 72% of available market products, improving affordability and patient accessibility. The expansion of healthcare infrastructure, rising geriatric population, and increasing musculoskeletal disorder incidence continue to positively influence the Indomethacin Tablets Market Growth and Market Outlook globally.

RESTRAINTS

"Gastrointestinal and cardiovascular side effects associated with NSAIDs"

Side effects linked to prolonged NSAID consumption remain a significant restraint for the Indomethacin Tablets Market. Nearly 37% of long-term NSAID users experience gastrointestinal complications such as ulcers, stomach irritation, nausea, and bleeding risks. Around 24% of elderly patients require physician-monitored dosage adjustments due to renal sensitivity and cardiovascular concerns. Clinical guidelines in multiple countries recommend cautious NSAID administration for patients with hypertension, kidney disorders, and gastric conditions, limiting prescription flexibility. Approximately 19% of healthcare providers prefer alternative pain management medications for high-risk patients. Regulatory monitoring of NSAID safety profiles continues to increase across pharmaceutical markets, resulting in stricter labeling and dosage control requirements. Additionally, patient awareness regarding side effects has increased substantially, influencing treatment preferences toward topical therapies and combination medications. More than 31% of healthcare professionals report concerns regarding long-term NSAID dependency among chronic pain patients. Competition from alternative anti-inflammatory therapies, biologics, and corticosteroid treatments also affects market penetration in specialized treatment segments. These factors collectively limit broader adoption despite strong demand for oral anti-inflammatory medications.

OPPORTUNITY

"Expansion of generic pharmaceutical manufacturing and enteric-coated formulations"

The growing expansion of generic pharmaceutical manufacturing presents substantial opportunities for the Indomethacin Tablets Market. More than 68% of global pharmaceutical consumption now involves generic medicines due to lower treatment costs and wider healthcare accessibility. Asia-Pacific pharmaceutical production hubs contribute significantly to worldwide tablet manufacturing, supporting higher export volumes and broader distribution networks. Enteric-coated formulations are witnessing strong demand because they reduce gastric irritation and improve patient compliance. Nearly 43% of newly approved NSAID tablet formulations include protective coating technologies designed to enhance tolerability. Healthcare systems in emerging economies are increasingly focusing on affordable chronic pain management solutions, supporting higher adoption of generic indomethacin products. Online pharmacy expansion and digital prescription platforms have increased patient access by approximately 26% across urban and semi-urban regions. Pharmaceutical companies are investing in advanced tablet compression technologies, stability improvements, and low-dose variants for elderly patients. Hospital procurement programs and public healthcare initiatives are also supporting bulk purchasing of anti-inflammatory medications. Rising investments in pharmaceutical research and improved regulatory harmonization across international markets continue creating strong opportunities for manufacturers operating in the Indomethacin Tablets Market Research Report ecosystem.

CHALLENGE

"Regulatory compliance and competition from alternative therapies"

The Indomethacin Tablets Market faces considerable challenges associated with regulatory compliance and increasing competition from alternative treatment therapies. Pharmaceutical manufacturers must comply with strict quality assurance standards, stability testing protocols, and safety monitoring regulations imposed by international healthcare authorities. Nearly 29% of manufacturers report delays in regulatory approvals for modified oral formulations. Product recalls associated with contamination risks and manufacturing inconsistencies also impact market reputation and supply continuity. Additionally, biologic drugs, corticosteroids, and topical anti-inflammatory therapies are increasingly preferred for specific patient groups due to reduced systemic side effects. Around 34% of rheumatologists now incorporate combination therapy approaches instead of relying solely on oral NSAIDs. Price competition among generic drug manufacturers is intensifying, reducing operational margins and increasing pressure on production efficiency. Raw material price fluctuations and pharmaceutical supply chain disruptions further affect manufacturing stability. Healthcare providers are also adopting personalized treatment protocols, requiring pharmaceutical companies to develop safer and more targeted anti-inflammatory products. These operational and competitive pressures continue challenging long-term expansion within the global Indomethacin Tablets Industry Analysis landscape.

Indomethacin Tablets Market Segmentation

The Indomethacin Tablets Market Segmentation is categorized by type and application based on formulation preference, therapeutic usage, patient tolerance, and prescription trends across healthcare settings. Standard indomethacin tablets remain widely used due to rapid anti-inflammatory effects and extensive physician familiarity. Enteric-coated tablets are increasingly preferred among elderly patients and individuals with gastrointestinal sensitivity. Application-based segmentation includes hospital pharmacies, retail pharmacies, online pharmacies, and specialty clinics. Retail pharmacies contribute substantial dispensing volumes due to higher chronic pain treatment demand. Hospitals account for strong prescription rates for post-operative inflammation management and arthritis treatment programs.

Download FREE Sample to learn more about this report.

BY TYPE

Indomethacin Tablets: Standard indomethacin tablets continue to maintain strong prescription demand due to rapid absorption characteristics and effective inflammation control capabilities. Approximately 57% of total NSAID oral anti-inflammatory prescriptions within this segment involve conventional indomethacin tablets. These formulations are commonly prescribed for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, bursitis, and acute gout conditions. More than 49% of hospital-based pain management protocols include immediate-release NSAID formulations because of their fast therapeutic action. Retail pharmacy sales contribute significantly to this segment due to high physician familiarity and broad generic product availability. Generic standard tablets account for nearly 74% of overall distribution volumes, supporting affordability in developing healthcare systems. Physicians frequently prescribe standard tablets for short-term inflammatory episodes and post-operative pain management. Around 41% of orthopedic treatment centers prefer conventional oral NSAID tablets for initial inflammation treatment. Improvements in tablet stability, packaging, and dosage flexibility continue supporting product demand globally. Increasing prevalence of chronic musculoskeletal disorders and rising outpatient treatment programs are further strengthening the adoption of standard indomethacin tablets across healthcare institutions and pharmacy distribution channels.

Indomethacin Enteric Coated Tablets: Indomethacin enteric coated tablets are experiencing growing adoption due to their enhanced gastrointestinal protection and improved patient tolerance. Approximately 43% of physicians now recommend coated NSAID formulations for elderly patients and individuals with gastric sensitivity concerns. Enteric coating technologies help minimize stomach irritation by delaying drug release until the tablet reaches the intestinal tract. Nearly 36% of chronic arthritis patients prefer coated tablets for long-term therapy management because of improved comfort during continuous usage. Pharmaceutical companies are increasingly investing in advanced coating technologies and controlled-release mechanisms to improve therapeutic outcomes and patient compliance. Hospital procurement programs for chronic inflammatory treatment have increased coated tablet purchases by approximately 28%. These formulations are particularly popular in developed healthcare markets where patient safety and medication tolerability remain major prescribing considerations. More than 33% of rheumatology specialists prioritize coated NSAID prescriptions for patients with a history of gastrointestinal complications. Expanding awareness regarding NSAID safety profiles and increasing physician preference for patient-friendly formulations continue to support strong growth potential for enteric coated indomethacin tablets across global pharmaceutical markets.

BY APPLICATION

Hospital: Hospitals remain one of the largest application segments within the Indomethacin Tablets Market due to the high volume of orthopedic surgeries, inflammatory disease treatments, trauma management, and post-operative pain therapies. Nearly 46% of indomethacin tablet prescriptions are generated through hospital-based healthcare systems. Around 61% of inpatient arthritis management programs include oral NSAID formulations as part of standard treatment protocols. Emergency departments and orthopedic wards continue to rely heavily on anti-inflammatory medications for acute pain reduction and inflammation control. Approximately 39% of post-surgical pain management procedures involve NSAID-based oral medications before transitioning patients to rehabilitation care. Hospital pharmacies contribute significantly to bulk procurement due to rising patient admissions associated with musculoskeletal disorders and sports injuries. More than 33% of rheumatology departments prefer indomethacin tablets for moderate inflammatory flare-up treatment because of rapid therapeutic response rates. Increasing healthcare infrastructure modernization and expansion of specialized orthopedic centers are strengthening demand for oral anti-inflammatory therapies. In addition, nearly 28% of geriatric patient care programs in hospitals involve long-term anti-inflammatory prescription management. Advanced digital prescription systems and improved medication monitoring practices continue supporting higher adoption of indomethacin tablets across hospital healthcare networks.

Clinic: Clinics represent a rapidly growing application segment within the Indomethacin Tablets Market due to increasing outpatient treatment volumes and growing diagnosis rates of arthritis and inflammatory disorders. Approximately 42% of chronic pain consultations in outpatient clinics involve NSAID prescription recommendations for inflammation and mobility improvement. Orthopedic clinics account for nearly 31% of oral anti-inflammatory tablet dispensing volumes globally. Rheumatology specialists in clinics frequently prescribe indomethacin tablets for osteoarthritis, gout attacks, bursitis, and tendon inflammation management. Around 47% of musculoskeletal disorder patients prefer clinic-based treatment due to faster consultation access and lower treatment complexity compared to hospital admission procedures. Pain management clinics continue expanding NSAID prescription rates because oral tablet formulations provide convenient administration and immediate symptom relief. Nearly 36% of sports medicine clinics use indomethacin tablets during rehabilitation treatment protocols for athletes and injury recovery patients. Increasing urbanization and rising access to private healthcare clinics are strengthening pharmaceutical distribution networks for anti-inflammatory medications. Clinics also contribute substantially to follow-up prescription renewals, particularly among elderly patients requiring continuous inflammation management. Telemedicine integration and electronic prescription systems have increased outpatient pharmaceutical accessibility by approximately 24%, supporting stronger penetration of indomethacin tablets across clinic environments.

Other: The other application segment includes retail healthcare centers, rehabilitation facilities, nursing homes, ambulatory surgical centers, and home healthcare programs that increasingly utilize indomethacin tablets for inflammation management and chronic pain control. Nearly 29% of long-term elderly care facilities incorporate oral NSAID medications into daily treatment programs for arthritis-related mobility support. Ambulatory surgical centers account for approximately 18% of anti-inflammatory medication prescriptions associated with outpatient orthopedic procedures and short-term recovery programs. Home healthcare treatment adoption has increased significantly due to rising elderly populations and improved pharmaceutical delivery services. Around 32% of chronic inflammatory patients now prefer home-based treatment and medication management programs for convenience and reduced hospitalization frequency. Rehabilitation centers increasingly use indomethacin tablets during physical therapy and recovery management for patients with musculoskeletal injuries. Retail healthcare clinics and pharmacy-led consultation services also contribute to prescription growth due to higher public awareness regarding pain management therapies. Approximately 26% of over-the-counter pain management inquiries result in physician-directed NSAID prescriptions through outpatient healthcare channels. Growing healthcare accessibility in semi-urban and rural regions continues expanding this application segment across global pharmaceutical distribution systems.

Indomethacin Tablets Market Regional Outlook

Download FREE Sample to learn more about this report.

North America

North America dominates the Indomethacin Tablets Market due to strong pharmaceutical infrastructure, high arthritis prevalence, and advanced healthcare accessibility. Approximately 39% of global anti-inflammatory tablet prescription volumes originate from North America. More than 58 million adults in the region suffer from arthritis-related conditions requiring regular pain management therapies. Hospital pharmacy distribution contributes nearly 44% of total regional NSAID dispensing volumes, while retail pharmacies account for approximately 41%. Generic drug penetration exceeds 87%, improving affordability and patient access to indomethacin formulations. Around 48% of orthopedic treatment procedures involve oral anti-inflammatory prescriptions during recovery management. The aging population continues increasing demand for chronic pain medications, with elderly individuals representing nearly 18% of the regional population. Specialty rheumatology clinics are expanding rapidly, supporting higher diagnosis rates for inflammatory disorders. Digital healthcare systems and electronic prescription platforms have improved pharmaceutical dispensing efficiency by approximately 29%. Pharmaceutical manufacturers continue focusing on coated formulations and patient-friendly dosage improvements, strengthening long-term market expansion throughout North America.

Europe

Europe represents a mature pharmaceutical market for indomethacin tablets due to increasing inflammatory disease treatment demand and widespread healthcare coverage systems. Approximately 34% of adults above 60 years in Europe experience chronic joint pain or arthritis-related mobility conditions. Public healthcare systems contribute significantly to NSAID prescription distribution through hospital and community pharmacy networks. Nearly 52% of anti-inflammatory drug prescriptions in the region involve oral tablet formulations because of strong physician familiarity and treatment effectiveness. Generic pharmaceutical adoption exceeds 74%, encouraging broader accessibility across Western and Eastern European healthcare systems. Orthopedic rehabilitation programs and post-surgical recovery therapies continue increasing demand for oral NSAIDs. Around 27% of pharmaceutical companies operating in Europe are investing in enteric-coated and controlled-release formulations to reduce gastrointestinal side effects. Retail pharmacies account for approximately 45% of tablet distribution volumes. The growing elderly population and rising obesity-related musculoskeletal disorders continue supporting prescription growth. Regulatory focus on medication safety and pharmaceutical quality standards is encouraging innovation in tablet formulation technologies throughout the European Indomethacin Tablets Market.

Asia-Pacific

Asia-Pacific is experiencing strong growth within the Indomethacin Tablets Market due to expanding healthcare infrastructure, rising generic pharmaceutical manufacturing, and increasing chronic disease prevalence. Approximately 34% of global generic NSAID production originates from Asia-Pacific manufacturing facilities. Countries across the region are witnessing higher diagnosis rates for arthritis and inflammatory conditions because of urbanization, aging populations, and lifestyle-related health disorders. More than 41% of regional pharmaceutical distribution involves generic oral tablet formulations due to affordability advantages. Retail pharmacies remain the dominant distribution channel, accounting for nearly 49% of prescription dispensing volumes. Hospital demand is also increasing significantly due to rising orthopedic surgeries and trauma care procedures. Around 37% of pharmaceutical manufacturers in the region are expanding production capacities for anti-inflammatory medications. Healthcare access improvements in rural areas and government-supported generic medicine programs are increasing patient treatment availability. Online pharmacy platforms and telemedicine integration have increased digital pharmaceutical purchases by approximately 31%. Continuous investments in pharmaceutical exports, coating technologies, and improved packaging solutions are strengthening Asia-Pacific’s role within the global Indomethacin Tablets Industry Analysis landscape.

Middle East & Africa

The Middle East & Africa region is gradually expanding within the Indomethacin Tablets Market due to improving healthcare access, increasing chronic disease awareness, and growing pharmaceutical imports. Approximately 23% of adults in urban healthcare centers report chronic musculoskeletal pain requiring anti-inflammatory treatment support. Hospital pharmacies contribute nearly 51% of regional oral NSAID distribution volumes because centralized healthcare systems dominate pharmaceutical procurement. Generic medicines account for approximately 63% of anti-inflammatory drug consumption due to affordability requirements across developing economies. Orthopedic injury cases related to road accidents and occupational activities continue increasing demand for pain management therapies. Around 28% of healthcare investments across the region are directed toward hospital modernization and pharmaceutical accessibility improvements. Retail pharmacy expansion and private healthcare clinic development are supporting broader availability of oral indomethacin products. Healthcare awareness campaigns have increased arthritis diagnosis rates by approximately 19% in major urban centers. Pharmaceutical partnerships and import agreements continue improving medicine supply continuity. Growing elderly populations, increasing obesity rates, and rising inflammatory disease incidence are expected to support long-term demand for indomethacin tablets throughout Middle East & Africa healthcare systems.

List of Key Indomethacin Tablets Market Companies

• Shanghai Xinyi Jiufu Pharmaceutical
• Hebei Yinengpu Pharmaceutical
• Huaan Pharmaceutical
• Jinhualong Pharmaceutical
• Aodong Yanbian Pharmaceutical
• Wanquan Wante Pharmaceutical
• Baizheng Pharmaceutical
• Chongqing Kerui Pharmaceutical
• Kowa Company
• Nipro Pharma Corporation
• Maeda Pharmaceutical

Top Companies with Highest Market Share

• Kowa Company: Approximately 18% of branded indomethacin prescription distribution across developed pharmaceutical markets is associated with Kowa Company due to extensive anti-inflammatory product portfolios, strong physician recognition, and advanced pharmaceutical manufacturing capabilities. The company maintains high penetration across hospital pharmacy networks and specialty rheumatology treatment centers.
• Nipro Pharma Corporation: Nearly 15% of generic anti-inflammatory tablet production within regulated pharmaceutical markets is attributed to Nipro Pharma Corporation. The company benefits from strong manufacturing efficiency, broad generic medicine distribution channels, and increasing adoption of coated tablet technologies focused on improved gastrointestinal tolerability and patient compliance.

Investment Analysis and Opportunities

The Indomethacin Tablets Market continues attracting pharmaceutical investments due to increasing inflammatory disease prevalence and expanding generic medicine demand. Approximately 46% of pharmaceutical investment programs targeting anti-inflammatory therapies are focused on oral NSAID production capacity expansion. Generic medicine manufacturing facilities are receiving substantial investments because nearly 72% of healthcare systems prioritize cost-effective treatment accessibility. Around 38% of pharmaceutical companies are increasing investments in enteric-coated tablet technologies to improve gastrointestinal safety and long-term patient compliance. Contract manufacturing partnerships have increased by approximately 27%, improving global pharmaceutical supply efficiency. Asia-Pacific remains a major investment destination due to lower manufacturing costs and expanding export capabilities. Digital pharmaceutical distribution systems and online pharmacy platforms are also attracting healthcare technology investments, with nearly 31% growth in electronic prescription integration initiatives. Hospital procurement modernization and healthcare infrastructure expansion across emerging economies continue creating favorable opportunities for pharmaceutical suppliers. Investments in research related to controlled-release formulations, improved packaging stability, and advanced tablet coating technologies are expected to strengthen competitive positioning within the global Indomethacin Tablets Market Forecast ecosystem.

New Products Development

New product development within the Indomethacin Tablets Market is increasingly focused on improving patient safety, reducing gastrointestinal complications, and enhancing therapeutic effectiveness. Approximately 43% of recently developed NSAID oral formulations involve enteric-coated technologies designed to minimize stomach irritation. Pharmaceutical companies are also introducing low-dose tablet variants targeted toward elderly populations and long-term arthritis management programs. Around 29% of ongoing product innovation initiatives involve controlled-release mechanisms to improve dosage consistency and reduce administration frequency. Manufacturers are investing heavily in advanced compression technologies that improve tablet dissolution efficiency and product stability during transportation and storage. Nearly 34% of anti-inflammatory pharmaceutical development projects now prioritize patient-friendly formulations with improved swallowing convenience and reduced adverse reactions. Pediatric-safe packaging systems and moisture-resistant blister technologies are also becoming increasingly common across pharmaceutical production lines. Online pharmacy integration and digital prescription compatibility are influencing packaging and labeling innovations. Companies are further focusing on environmentally sustainable manufacturing practices, with approximately 22% of pharmaceutical facilities implementing reduced-emission production systems for oral tablet manufacturing operations.

Five Recent Developments(2023-2025)

• Advanced Enteric Coating Expansion: During 2024, approximately 33% of pharmaceutical manufacturers increased production of enteric-coated indomethacin tablets to address rising gastrointestinal safety concerns among long-term NSAID users. Enhanced coating technologies improved tablet stability by nearly 21% and increased patient compliance rates across arthritis treatment programs.
• Hospital Distribution Network Modernization: In 2024, nearly 28% of hospital pharmacy systems implemented upgraded digital inventory management for anti-inflammatory medications. Automated prescription systems improved medication tracking efficiency by approximately 24%, reducing dispensing delays for indomethacin-based therapies across orthopedic and rheumatology departments.
• Generic Manufacturing Capacity Expansion: Between 2023 and 2024, approximately 37% of generic pharmaceutical producers expanded oral NSAID manufacturing lines due to increasing global demand for cost-effective anti-inflammatory therapies. Producti

  Indomethacin Tablets Market Report Coverage

  REPORT COVERAGE	DETAILS
  Market Size Value In	USD 514.86 Million in 2026
  Market Size Value By	USD 813.4 Million by 2035
  Growth Rate	CAGR of 5.22% from 2026 - 2035
  Forecast Period	2026 - 2035
  Base Year	2025
  Historical Data Available	Yes
  Regional Scope	Global
  Segments Covered
  	By Type Indomethacin Tablets Indomethacin Enteric Coated Tablets
  	By Application Hospital Clinic Other